Dyax is a fully integrated biopharmaceutical company focused on developing and commercializing products for unmet medical needs. We currently market a product for the treatment of acute attacks of hereditary angioedema (HAE), a rare genetic disease (to learn more, click here). We also have an investigational drug candidate in development for the prevention of HAE attacks (to learn more, click here).
Both our commercial product and drug candidate in development were identified using Dyax’s proprietary phage display technology. We have broadly licensed this technology and have a portfolio of product candidates being developed by our licensees that we refer to as the Licensing and Funded Research Portfolio (LFRP). This portfolio includes one approved product for which we receive royalties. Additionally, there are multiple product candidates in various stages of clinical development for which we are eligible to receive future milestones and/or royalties (to learn more, click here).
More »Stock Quote
|DYAX (Common Stock)|
|Exchange||NASDAQ (US Dollars)|
|Change (%)||0.07 (-0.43)%|
|Data as of Dec 22, 2014 10:55 AM ET
Delayed at least 20 minutes. Provided by eSignal.
More »Recent Releases
More »Calendar of Events
|Details on upcoming events are not yet available.|
More » Event Archives
||Oppenheimer & Co. Inc. 25th Annual Healthcare Conference|
||Dyax Corp. 3Q 2014 Earnings Call|
||Leerink Partners Rare Disease Roundtable|
||Dyax Corp. 2Q 2014 Earnings Call|
Featured Financial Reports
|Nov 3, 2014||10-Q||530.9 KB|
|Dec 31, 2013||2013 Annual Report||508.9 KB|